AstraZeneca: ENHERTU Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
October 24, 2023
October 24, 2023
WILMINGTON, Delaware, Oct. 24 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Oct. 23, 2023:
* * *
AstraZeneca and Daiichi Sankyo's ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
Results reaffirm potential role of ENHERTU as a tumor-agnostic therapy for previously treated patients with HER2-expressing solid tumors and suppor . . .
* * *
AstraZeneca and Daiichi Sankyo's ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
Results reaffirm potential role of ENHERTU as a tumor-agnostic therapy for previously treated patients with HER2-expressing solid tumors and suppor . . .